Inhibitor of p38 map kinase

Patent metadata

Field	Value
Publication number	US-9447076-B2
Application number	US-201514622368-A
Country	US
Kind code	B2
Filing date	Feb 13, 2015
Priority date	Feb 14, 2014
Publication date	Sep 20, 2016
Grant date	Sep 20, 2016

Abstract

A compound has the following formula:

The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.

First claim

What is claimed is:

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 in the form of its maleate salt.

3. A compound according to claim 2 in the form of its Form 2 crystalline polymorph.

4. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 in combination with one or more pharmaceutically acceptable diluents or carriers.

5. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 in particulate form in combination with particulate lactose.

6. A pharmaceutical composition according to claim 5 further comprising particulate magnesium stearate.

7. A combination product comprising:
(A) a compound according to claim 1 ; and
(B) one or more other therapeutic agents,
wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

8. A method of treatment of a condition selected from COPD and asthma which comprises administering to a subject an effective amount of a compound according to claim 1 .

9. A pharmaceutical composition according to claim 4 wherein the compound of formula (I) is in the form of its maleate salt.

10. A pharmaceutical composition according to claim 5 wherein the compound of formula (I) is in the form of its maleate salt.

11. A pharmaceutical composition according to claim 6 wherein the compound of formula (I) is in the form of its maleate salt.

12. A combination product according to claim 7 wherein the compound of formula (I) is in the form of its maleate salt.

13. A method according to claim 8 wherein the compound of formula (I) is in the form of its maleate salt.

14. A pharmaceutical composition according to claim 9 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.

15. A pharmaceutical composition according to claim 10 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.

16. A pharmaceutical composition according to claim 11 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.

17. A combination product according to claim 12 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.

18. A method according to claim 13 wherein the compound of formula (I) maleate salt is in the form of its Form 2 crystalline polymorph.

Assignees

• Respivert Ltd
• Topivert Pharma Ltd
• Respivert Ltd

Inventors

• Longshaw Alistair Ian
• Fordyce Euan Alexander Fraser
• Onions Stuart Thomas
• King-Underwood John
• Venable Jennifer

Classifications

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K31/551

  having two nitrogen atoms, e.g. dilazep · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61K31/215

  of carboxylic acids · CPC title

• A61K31/498

  Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine · CPC title